home / stock / bsem / bsem news

BSEM News and Press, BioStem Technologies Inc From 03/31/25

Stock Information
Company Name: BioStem Technologies Inc
Stock Symbol: BSEM
Market: OTC
Website: biostemtechnologies.com
Menu
BSEM BSEM Quote BSEM Short BSEM News BSEM Articles BSEM Message Board
Get BSEM Alerts

News, Short Squeeze, Breakout and More Instantly...
BSEM - BioStem Announces Notice of Allowance for Two U.S. Patent Applications

POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and T...
BSEM - BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference

POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that its Chief Executive Officer, Jason M...

BSEM - BioStem Technologies: Building On Advanced Wound Care Needs

2025-03-17 01:19:57 ET Summary BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing...

BSEM - BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval ...
BSEM - BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-deri...

BSEM - BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain...

BSEM - BioStem Technologies CEO to Present at Biotech Showcase 2025

POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’...
Previous 10 Next 10